Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics (TVRD) filed Amendment No. 2 to a Form S-1 to register the resale of up to 2,084,117 shares of common stock issued to certain holders in connection with its April 2025 merger. The company states it will not receive any proceeds from sales under this prospectus; selling stockholders will pay any commissions and discounts.
The shares may be sold from time to time using various methods and prices. Tvardi’s common stock trades on Nasdaq as TVRD; the last quoted sale price was $6.58 on October 17, 2025. Following the merger and a 1‑for‑3 reverse stock split, 9,355,542 shares were issued and outstanding immediately after the effective time.
Tvardi is a clinical‑stage biopharma developing oral STAT3 inhibitors. Lead candidate TTI‑101 is in Phase 2 for HCC with FDA Fast Track and orphan designations; the company reported preliminary Phase 2 IPF data in October 2025 and concluded the study did not meet its goals. Risk disclosures note substantial doubt about the company’s ability to continue as a going concern and the need for additional capital.
Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K announcing a press release about preliminary data from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis. The company stated the full text of the press release, titled “Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis,” is furnished as Exhibit 99.1 and incorporated by reference.
Tvardi Therapeutics (TVRD) filed an amended S-1 that stresses the company is an early-stage clinical biotechnology company with no product revenue, an accumulated deficit of $92.2M and cash resources that management deems insufficient to fund operations for at least one year, creating substantial doubt about its ability to continue as a going concern. The filing describes lead programs TTI-101 (oral STAT3 inhibitor) and TTI-109, development plans in IPF and HCC, regulatory designations (orphan and Fast Track for TTI-101 in select indications), and trial timelines: a 12-week REVERT IPF Phase 2 study (38 randomized patients) with preliminary blinded data showing ~50% of participants near or above baseline FVC and an expected unblinded readout in Q4 2025, and a REVERT HCC Phase 1b/2 program with preliminary topline data expected in H1 2026. The company disclosed material financing instruments: Convertible Notes with $28.3M principal (fair-valued to $30.1M at year-end), 8% interest, and conversion mechanics tied to Qualified Financings, an IPO, or a reverse merger. The S-1/A also describes the Merger that converted Legacy Tvardi equity into Cara shares, acquisition of approximately $23.9M in net assets, historical financings including Series A ($8.4M) and Series B ($66.3M), identified material weaknesses in legacy internal controls, and broad risk factors tied to clinical, regulatory, manufacturing, IP and commercialization challenges.
Tvardi Therapeutics, Inc. filed a Form 8-K to furnish a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The company, formerly known as Cara Therapeutics, issued the release on August 14, 2025, and attached it as Exhibit 99.1.
The disclosure is provided under Item 2.02, "Results of Operations and Financial Condition," and is expressly described as being "furnished" rather than "filed," which limits its applicability for certain securities law liability provisions and for automatic incorporation by reference into other SEC filings.
Slate Path Capital LP and David Greenspan report owning 704,118 shares (7.5%) of Tvardi Therapeutics (TVRD). The holdings are held by Slate Path Master Fund LP and SPB Master Fund LP and are reported as shared voting and dispositive power; neither reporting person claims sole voting or dispositive power. The percentage is calculated using 9,360,904 shares outstanding as of May 8, 2025. The filing states the shares were acquired in the ordinary course of business and were not acquired to change or influence control of the company.
Sporos Bioventures LLC reported direct beneficial ownership of 837,636 shares of Tvardi Therapeutics common stock, equal to 8.95% of the outstanding class. The filer discloses sole voting power and sole dispositive power over these shares, and reports no shared voting or dispositive arrangements.
This Schedule 13G statement records a material, reportable passive stake above the 5% threshold and provides investors with clear disclosure of concentrated ownership and voting control of a meaningful minority position in TVRD.
Schedule 13G/A (Amendment 1) discloses the current ownership of Tvardi Therapeutics, Inc. (TVRD) by Samuel D. Tweardy.
The filer reports 315,658 common shares, held via the Samuel David Tweardy 2020 Gift Trust, representing 3.4 % of the 9,373,433 shares outstanding as of 8 Aug 2025. He retains sole voting and dispositive power over the entire stake; no shared power is indicated.
Tweardy resigned as trustee of two related 2020 Gift Trusts—actions permitted under an existing 17 Dec 2024 lock-up agreement—so those trusts’ shares are no longer included in his beneficial ownership. Item 5 confirms the position is now 5 % or less of the class, qualifying the filing for passive Schedule 13G treatment. The certification states the shares were not acquired to influence control of the issuer.
Tvardi Therapeutics (TVRD) – Form 4 insider update: Director & 10% owner Samuel D. Tweardy disclosed that on 07 Jul 2025 he resigned as trustee of a family trust holding 315,658 common shares. Transaction code “J” indicates a transfer with no monetary consideration; stated price $0. Because the shares are now held by the trust without Tweardy’s control, his reported beneficial ownership fell from 315,658 shares to zero. The stock remains locked-up under the 17 Dec 2024 agreement, so the float is unchanged. No derivative positions or additional transactions were reported. While the filing does not reflect an open-market sale, it removes a sizable insider stake, potentially reducing insider–shareholder alignment. The document contains no operating or financial performance data.